摘要Objective To compare the therapeutic efficacy of portal and tail vein transplantation of bone marrow-derived mesenchymal stem cells(BMSCs)against cholestatic liver fibrosis in mice.Methods BMSCs were isolated and co-cultured with starvation-activated hepatic stellate cells(HSCs).HSC activation markers were identified using immunofluorescence and qRT-PCR.BMSCs were injected into the liver tissues of bile duct ligation(BDL)mice via the tail and portal veins.Histomorphology,liver function,inflammatory cytokines,and the expression of key proteins were all determined in the liver tissues.Results BMSCs inhibited HSC activation by reducing α-SMA and collagen I expression.Compared to tail vein injection,DIL-labeled BMSCs injected through the portal vein maintained a high homing rate in the liver.Moreover,BMSCs transplanted through the portal vein resulted in greater improvement in liver color,hardness,and gallbladder size than did those transplanted through the tail vein.Furthermore,BMSCs injected by portal vein,but not tail vein,markedly ameliorated liver function,reduced the secretion of inflammatory cytokines,including TNF-α,IL-6,and IL-1β,and decreased α-SMA+hepatic stellate cell(HSC)activation and collagen fiber formation.Conclusion The therapeutic effect of BMSCs on cholestatic liver fibrosis in mice via portal vein transplantation was superior to that of tail vein transplantation.This comparative study provides reference information for further BMSC studies focused on clinical cholestatic liver diseases.